rhodoxanthin: RN given refers to (all-trans)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5281251 |
CHEBI ID | 8835 |
SCHEMBL ID | 42598 |
MeSH ID | M0114749 |
Synonym |
---|
LMPR01070280 |
C08610 |
rhodoxanthin |
116-30-3 |
(4e)-3,5,5-trimethyl-4-[(2e,4e,6e,8e,10e,12e,14e,16e,18e)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-4-oxocyclohex-2-en-1-ylidene)octadeca-2,4,6,8,10,12,14,16-octaenylidene]cyclohex-2-en-1-one |
4,5'-retro-beta,beta-carotene-3,3'-dione, 4',5'-didehydro- |
51v984id9q , |
unii-51v984id9q |
e-161f |
4,7'-retro-.beta.,.epsilon.-carotene-3,3'-dion |
rhodoxanthin [mi] |
SCHEMBL42598 |
VWXMLZQUDPCJPL-ZDHAIZATSA-N |
CHEBI:8835 |
Q2479965 |
DTXSID201017050 |
Rhodoxanthin is a scarcely explored carotenoid. It has an extraordinarily large chromophore and high potential to function as red pigment.
Excerpt | Reference | Relevance |
---|---|---|
"Rhodoxanthin is a scarcely explored carotenoid with an extraordinarily large chromophore and high potential to function as red pigment. " | ( The impact of (E/Z)-isomerization and aggregation on the color of rhodoxanthin formulations for food and beverages. Bonrath, W; Schäfer, C; Schex, R; Schweiggert, R, 2020) | 2.24 |
Class | Description |
---|---|
xanthophyll | A subclass of carotenoids consisting of the oxygenated carotenes. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (15.38) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 3 (23.08) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.02) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |